More on the Work of the Longevity Escape Velocity Foundation

The Longevity Escape Velocity Foundation (LEVF) is initially working to assess combinations of approaches to the treatment of aging, to assess the degree to which mouse life span is affected. Aging consists of many distinct mechanisms, and comprehensive rejuvenation will require a diverse package of therapies. Yet the research and development community undertakes little work on combined treatments. Here, the Lifespan.io team talks to Aubrey de Grey about some of the details of the work presently under way. We are obviously very excited about LEVF's robust mouse rejuvenation (RMR) project. Could you walk our readers through its design and goals? This is envisioned as a rolling research program aiming to increase both the mean and maximum lifespan of mice by at least 12 months with various combination therapies started late in life. For the first study, four therapies have been chosen: rapamycin, a senolytic, hematopoietic stem cell transplantation (HSCT), and telomerase expression. I believe we'll have two outcomes. One of them scientific, and the other more, if you like, rhetorical. We want to get mice to live a lot longer than they do now: at least a year longer, starting the treatment or treatments only after middle age. The idea is that this will appeal more directly to people who care, vote, pay taxes, and make donations than if you do early-onset interventions. So, I decided to put numbers on this, to have a milestone that clearly says this is where we wa...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs